Halozyme Therapeutics, Inc. (NASDAQ:HALO) , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA.
The study showed that treatment of hormone resistant human prostate cancer in tumor bearing mouse models with intravenous PEGPH20 in combination with the chemotherapeutic drugs, docetaxel (Taxotere ) or liposomal doxorubicin (Doxil ) resulted in a substantial increase in anti-tumor activity. The docetaxel combination treatment demonstrated significantly enhanced survival compared to treatment with the chemotherapeutic agent alone.
The effects of PEGPH20 were selective to prostate tumors producing hyaluronan (HA), consistent with the selective reduction of tumor interstitial fluid pressure (IFP). Treatment with PEGPH20 was well tolerated in non tumor-bearing mice without significant increases in neutropenia (depletion of neutrophils, a type of white blood cell) compared to chemotherapy alone.
No User Responded In This Post
Leave Your Comments Here...